Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | PTGER1 | P34995 | 12/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MASP2 | O00187 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4656398 | 0.92 | PTGER1 (0.52) | PTGER1MASP2F2 | |
| SCHEMBL2946766 | 0.85 | MAPT (0.58) | MAPTPTGER1F2TDP1 | |
| SCHEMBL2941158 | 0.83 | MEN1 (0.53) | MAPTHPGDCYP3A4PTGER1MEN1 | |
| SCHEMBL4910758 | 0.82 | PTGER1 (0.49) | MAPTPTGER1 | |
| SCHEMBL11069880 | 0.81 | PTGER1 (0.54) | MAPTHPGDCYP3A4PTGER1MEN1 | |
| SCHEMBL2945003 | 0.80 | PTGER1 (0.47) | PTGER1MASP2F2 | |
| SCHEMBL2944820 | 0.79 | PTGDR2 (0.52) | MAPTHPGDPTGER1MEN1KMT2A | |
| SCHEMBL4626795 | 0.78 | PTGER1 (0.47) | MAPTPTGER1MEN1KMT2AALDH1A1 | |
| SCHEMBL4627361 | 0.78 | PTGDR (0.58) | MAPTCYP1A2F2ALDH1A1TDP1 | |
| SCHEMBL4627039 | 0.78 | PTGDR2 (0.52) | MAPTMEN1KMT2AF2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312322-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-12-18 | — | — | US | disclosed |
| EP-1888505-A1 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006125593-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312322-A1 | Organic Compounds | NR3C2, MRGPRX2, HRH2 | MAPT 4232/4885HPGD 525/4885CYP1A2 1094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.